Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

Abstract:
Carigent Therapeutics, Inc., announced today that the National Cancer Institute of the National Institutes of Health has awarded Carigent a one-year, $153,000 Phase I Small Business Innovation Research (SBIR) grant to advance preclinical development of an innovative, long-circulating nanoparticle therapeutic that targets the specific molecular lesions in non-Hodgkin's lymphoma (NHL) patients.

Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

New Haven, CT | Posted on January 16th, 2008

Carigent's novel therapeutic approach is based on the company's proprietary technology for engineering biodegradable nanoparticles with exceptionally high-density surface modifications. The platform enables Carigent to design customized, multifunctional nanoscale carriers with the unique combined capability of:
Tethering multiple "functional groups" such as targeting ligands, diagnostic imaging agents, and polyethylene glycol (PEG) to the nanoparticle surface at previously unattainable densities, and Encapsulating single or combined therapeutic and/or diagnostic agents inside the nanoparticle for sustained, controlled release directly into targeted (i.e., diseased) tissues and cells.

"Non-Hodgkin's lymphoma has one of the fastest-growing incidence rates among cancers and is now the sixth most common cancer in the U.S.," said Seth Feuerstein, MD, JD, President and a co-founder of Carigent. "As we accelerate development of Carigent's engineered nanoparticle therapeutics to address unmet needs in cancer treatment, we are grateful for this financial support from the National Cancer Institute and the additional validation it provides Carigent's versatile nanoparticle delivery technology. The ability to modify particles for targeting as well as increased circulation time is what makes this an exciting project for the field."

####

About Carigent Therapeutics, Inc.
Carigent Therapeutics, Inc. is a biotechnology company developing and commercializing safer and more effective therapeutic and diagnostic products based on the company’s platform technology: Nanoparticles that enable delivery and controlled release of therapeutic and diagnostic agents into specific locations within the body and tissues. The company’s products and services are based on novel nanotechnology developed at Yale University that provides the unique capability of tethering agents for targeting, imaging, and increased circulation time at unprecedented densities to the surface of biodegradable polymer nanoparticles, resulting in drugs that bind to their targets more effectively, are delivered at a higher concentration to the desired location, and/or remain in the bloodstream longer than other nanotechnology-based drugs. The Carigent technology is broadly applicable across a wide variety of disease states and supports multiple types of targeting strategies and carrier designs for existing drugs as well as new drugs in development. Carigent’s initial product development programs are focused on cancer therapeutics. In parallel, Carigent provides access to its nanoparticle drug delivery technology through collaborations and partnerships with pharmaceutical, biotechnology, and diagnostics companies. Carigent was established in 2007 and is based in New Haven, Connecticut.

For more information, please click here

Contacts:
Mary Moynihan
M2Friend Biocommunications
(802) 951-9600

Copyright © Carigent Therapeutics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Govt.-Legislation/Regulation/Funding/Policy

NNCO Announces an Interactive Webinar: Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy July 23rd, 2014

Nano-sized Chip "Sniffs Out" Explosives Far Better than Trained Dogs: TAU researcher's groundbreaking sensor detects miniscule concentrations of hazardous materials in the air July 23rd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014

Nanomedicine

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Announcements

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

EPFL Research on the use of AFM based nanoscale IR spectroscopy for the study of single amyloid molecules wins poster competition at Swiss Physics Society meeting July 22nd, 2014

Carbyne morphs when stretched: Rice University calculations show carbon-atom chain would go metal to semiconductor July 21st, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE